95 related articles for article (PubMed ID: 18418213)
61. Optimal standard regimen and predicting response to docetaxel therapy.
Moawad EY
Mutat Res; 2014 Dec; 770():120-7. PubMed ID: 25771878
[TBL] [Abstract][Full Text] [Related]
62. AZD5582, an IAP antagonist that leads to apoptosis in head and neck squamous cell carcinoma cell lines and is eligible for combination with irradiation.
Kadletz L; Enzenhofer E; Kotowski U; Altorjai G; Heiduschka G
Acta Otolaryngol; 2017 Mar; 137(3):320-325. PubMed ID: 27739348
[TBL] [Abstract][Full Text] [Related]
63. Docetaxel influences autocrine of transforming growth factors and induces apoptosis in human ovarian cancer cell line AO.
Zhang Y; Hu YL; Cheng YY
Chin Med Sci J; 2006 Sep; 21(3):204. PubMed ID: 17086747
[No Abstract] [Full Text] [Related]
64. Verapamil (VER) Enhances the Cytotoxic Effects of Docetaxel and Vinblastine Combined Therapy Against Non-Small Cell Lung Cancer Cell Lines.
Jaferian S; Soleymaninejad M; Daraee H
Drug Res (Stuttg); 2018 Mar; 68(3):146-152. PubMed ID: 29132176
[TBL] [Abstract][Full Text] [Related]
65. [Focus on cellular pharmacology of docetaxel].
Armand JP
Bull Cancer; 2003 Dec; 90(12):1067-70. PubMed ID: 14715427
[TBL] [Abstract][Full Text] [Related]
66. Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in BXPC-3 and PANC-1 human pancreatic cancer cells.
Wang L; Zhu ZX; Zhang WY; Zhang WM
Exp Ther Med; 2011 Sep; 2(5):969-975. PubMed ID: 22977607
[TBL] [Abstract][Full Text] [Related]
67. The inhibitors of KDM4 and KDM6 histone lysine demethylases enhance the anti-growth effects of erlotinib and HS-173 in head and neck cancer cells.
Kleszcz R; Skalski M; Krajka-Kuźniak V; Paluszczak J
Eur J Pharm Sci; 2021 Nov; 166():105961. PubMed ID: 34363938
[TBL] [Abstract][Full Text] [Related]
68. Enhanced chemotherapeutic efficacy of docetaxel in human lung cancer cell line via GLUT1 inhibitor.
Bahremani M; Rashtchizadeh N; Sabzichi M; Vatankhah AM; Danaiyan S; Poursistany H; Mohammadian J; Ghorbanihaghjo A
J Biochem Mol Toxicol; 2023 Jun; 37(6):e23348. PubMed ID: 36999407
[TBL] [Abstract][Full Text] [Related]
69. Intravital FRET imaging of tumor cell viability and mitosis during chemotherapy.
Janssen A; Beerling E; Medema R; van Rheenen J
PLoS One; 2013; 8(5):e64029. PubMed ID: 23691140
[TBL] [Abstract][Full Text] [Related]
70. Combined effects of EGFR and hedgehog signaling blockade on inhibition of head and neck squamous cell carcinoma.
Liu J; Xie Y; Wu S; Lv D; Wei X; Chen F; Wang Z
Int J Clin Exp Pathol; 2017; 10(9):9816-9828. PubMed ID: 31966869
[TBL] [Abstract][Full Text] [Related]
71. Analysis of application of docetaxel combined therapy scheme in treating advanced head and neck neoplasm.
Nie L; Liu Y
Pak J Pharm Sci; 2016 Nov; 29(6 Spec):2231-2234. PubMed ID: 28412686
[TBL] [Abstract][Full Text] [Related]
72. Correction:
Anisuzzaman ASM; Haque A; Wang D; Rahman MA; Zhang C; Chen Z; Chen ZG; Shin DM; Amin ARMR
Mol Cancer Ther; 2020 Sep; 19(9):1955. PubMed ID: 32879030
[No Abstract] [Full Text] [Related]
73. Correction to: Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid Tumors.
Patnaik A; Gadgeel S; Papadopoulos KP; Rasco DW; Haas NB; Der-Torossian H; Faltaos D; Potvin D; Tassell V; Tawashi M; Chao R; O'Dwyer PJ
Target Oncol; 2022 Mar; 17(2):139. PubMed ID: 35380379
[No Abstract] [Full Text] [Related]
74. Anti-tumor activity of high-dose EGFR tyrosine kinase inhibitor and sequential docetaxel in wild type EGFR non-small cell lung cancer cell nude mouse xenografts.
Tang N; Zhang Q; Fang S; Han X; Wang Z
Oncotarget; 2017 Feb; 8(6):9134-9143. PubMed ID: 27852073
[TBL] [Abstract][Full Text] [Related]
75. Schedule-dependent cytotoxicity of sunitinib and TRAIL in human non-small cell lung cancer cells with or without EGFR and KRAS mutations.
Bao YX; Zhao XD; Deng HB; Lu CL; Guo Y; Lu X; Deng LL
Cell Oncol (Dordr); 2016 Aug; 39(4):343-52. PubMed ID: 27016208
[TBL] [Abstract][Full Text] [Related]
76. Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial.
Argiris A; Ghebremichael M; Gilbert J; Lee JW; Sachidanandam K; Kolesar JM; Burtness B; Forastiere AA
J Clin Oncol; 2013 Apr; 31(11):1405-14. PubMed ID: 23460714
[TBL] [Abstract][Full Text] [Related]
77. Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation.
Pan F; Tian J; Zhang X; Zhang Y; Pan Y
J Cancer Res Clin Oncol; 2011 Sep; 137(9):1397-408. PubMed ID: 21796416
[TBL] [Abstract][Full Text] [Related]
78. Concurrent and sequential administration of sunitinib malate and docetaxel in human non-small cell lung cancer cells and xenografts.
Wang D; Jiang Z; Zhang L
Med Oncol; 2012 Jun; 29(2):600-6. PubMed ID: 21455800
[TBL] [Abstract][Full Text] [Related]
79. Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer.
Byers LA; Sen B; Saigal B; Diao L; Wang J; Nanjundan M; Cascone T; Mills GB; Heymach JV; Johnson FM
Clin Cancer Res; 2009 Nov; 15(22):6852-61. PubMed ID: 19861436
[TBL] [Abstract][Full Text] [Related]
80. Sustained Src inhibition results in signal transducer and activator of transcription 3 (STAT3) activation and cancer cell survival via altered Janus-activated kinase-STAT3 binding.
Sen B; Saigal B; Parikh N; Gallick G; Johnson FM
Cancer Res; 2009 Mar; 69(5):1958-65. PubMed ID: 19223541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
